Evaluate

April 16, 2023

AACR 2023 – more hope for Moderna’s neoantigen immunotherapy

After Moderna/Merck & Co’s December splash, full data from Keynote-942 stand up to scrutiny.

April 06, 2023

The Covid crash continues

Pfizer keeps declining, but it is not the only pandemic player to suffer.

April 03, 2023

US FDA approval and panel tracker: March 2023

March 28, 2023

Profitability and pipeline in focus at post-pandemic Biontech

March 27, 2023

Key second-quarter clinical readouts for pharma

Lilly’s Alzheimer's and obesity results, outcomes for Novo Nordisk and oncology data for Merck & Co and Astrazeneca.

March 22, 2023

Second pivotal hit brings Claudin18.2 closer to approval

February 17, 2023

Moderna’s post-Covid prospects dim

January 31, 2023

Pfizer faces the Covid trough

January 20, 2023

Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression

39% of the patients assessed carried this biomarker, the conference presentation reveals.